Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQST NASDAQ:AVEO NASDAQ:SCPH NASDAQ:SESN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.05+2.0%$4.12$2.12▼$5.80$493.63M1.822.29 million shs2.68 million shsAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsSCPHscPharmaceuticals$5.63$5.07$1.94▼$6.28$300.07M0.352.31 million shs412,213 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+2.02%-6.83%+25.94%+47.66%+2.02%AVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SCPHscPharmaceuticals0.00%+1.08%+17.78%+42.53%+10.18%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$5.05+2.0%$4.12$2.12▼$5.80$493.63M1.822.29 million shs2.68 million shsAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsSCPHscPharmaceuticals$5.63$5.07$1.94▼$6.28$300.07M0.352.31 million shs412,213 shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+2.02%-6.83%+25.94%+47.66%+2.02%AVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SCPHscPharmaceuticals0.00%+1.08%+17.78%+42.53%+10.18%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.00Buy$10.29103.68% UpsideAVEOAVEO Pharmaceuticals 0.00N/AN/AN/ASCPHscPharmaceuticals 2.00Hold$7.7838.25% UpsideSESNSesen Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AQST, SCPH, AVEO, and SESN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025AQSTAquestive TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.009/3/2025AQSTAquestive TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$5.358/25/2025SCPHscPharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$6.008/25/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/13/2025AQSTAquestive TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/17/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$44.13M11.41N/AN/A($0.66) per share-7.65AVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28SCPHscPharmaceuticals$36.33M8.26N/AN/A$0.27 per share20.85SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$44.14M-$0.70N/AN/AN/A-147.38%N/A-63.87%11/3/2025 (Estimated)AVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ASCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)SESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ALatest AQST, SCPH, AVEO, and SESN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AQSTAquestive Therapeutics-$0.18-$0.14+$0.04-$0.14$11.32 million$10.00 million8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A3.533.18AVEOAVEO Pharmaceuticals0.942.372.35SCPHscPharmaceuticals3.863.853.14SESNSesen BioN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%AVEOAVEO Pharmaceuticals49.95%SCPHscPharmaceuticals89.52%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics8.35%AVEOAVEO Pharmaceuticals3.29%SCPHscPharmaceuticals4.78%SESNSesen Bio3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16099.72 million91.40 millionOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableAQST, SCPH, AVEO, and SESN HeadlinesRecent News About These CompaniesTrey MewesApril 9, 2024 | startribune.comSDevin Haney: biography, record, fights and moreDecember 9, 2023 | espn.comTyson Fury: Biography, record, fights and moreDecember 2, 2023 | espn.comWhy the Tucker Carlson Biography Sales Are So PatheticSeptember 13, 2023 | thedailybeast.comTSesen Bio (NASDAQ: SESN)August 4, 2023 | fool.comJames McTeigue Biography & MoviesMay 10, 2023 | tribute.caTAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 6, 2023 | bizjournals.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | msn.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsMarch 2, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 28, 2023 | finance.yahoo.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 24, 2023 | benzinga.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaFebruary 21, 2023 | finance.yahoo.comBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 17, 2023 | stockhouse.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | businesswire.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 16, 2023 | finance.yahoo.comSesen Bio reaches deal with investor group, paving way for Carisma mergerFebruary 15, 2023 | endpts.comELatest terms of Sesen Bio and Carisma merger appear to pass musterFebruary 15, 2023 | thepharmaletter.comT5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 15, 2023 | finance.yahoo.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAQST, SCPH, AVEO, and SESN Company DescriptionsAquestive Therapeutics NASDAQ:AQST$5.05 +0.10 (+2.02%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.16 +0.11 (+2.08%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.AVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.scPharmaceuticals NASDAQ:SCPH$5.63 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.62 0.00 (-0.09%) As of 09/12/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Sesen Bio NASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
